Opinion|Videos|April 17, 2026
NCCN Guidelines and HER2-Mutant NSCLC Management
Author(s)Martin Dietrich, MD, PhD, Ticiana A. Leal, MD
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, discuss how the NCCN Guidelines can help supplement HER2-mutant non–small cell lung cancer management decisions.
Advertisement
Episodes in this series
Martin F. Dietrich, MD, PhD, and Ticiana Leal, MD, review the role of NCCN Guidelines in informing treatment decisions for HER2-mutant non–small cell lung cancer. Dietrich highlights how guideline recommendations help standardize care in a rapidly evolving therapeutic landscape. Leal notes that while guidelines provide a useful framework, clinical judgment remains essential given ongoing data maturation and limited head-to-head comparisons.
Advertisement
Related to this article
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5